The Biotech Growth Trust (LON:BIOG) Stock Price Passes Below 200 Day Moving Average – Time to Sell?

The Biotech Growth Trust PLC (LON:BIOG)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 958.04 ($12.06) and traded as low as GBX 850.45 ($10.70). The Biotech Growth Trust shares last traded at GBX 852 ($10.72), with a volume of 48,347 shares changing hands.

The Biotech Growth Trust Price Performance

The firm’s fifty day simple moving average is GBX 869.02 and its two-hundred day simple moving average is GBX 958.04. The firm has a market cap of £243.41 million, a PE ratio of 2.86 and a beta of 0.50. The company has a quick ratio of 0.00, a current ratio of 0.59 and a debt-to-equity ratio of 11.02.

The Biotech Growth Trust (LON:BIOG) last released its quarterly earnings data on Wednesday, November 27th. The company reported GBX 0.20 ($0.00) earnings per share for the quarter. The Biotech Growth Trust had a net margin of 95.33% and a return on equity of 26.96%.

Insiders Place Their Bets

In other news, insider Nicola Shepherd bought 1,000 shares of The Biotech Growth Trust stock in a transaction on Monday, January 13th. The stock was acquired at an average cost of GBX 846 ($10.65) per share, for a total transaction of £8,460 ($10,648.21). Also, insider Julie Tankard bought 1,022 shares of The Biotech Growth Trust stock in a transaction on Wednesday, December 4th. The stock was purchased at an average price of GBX 972 ($12.23) per share, with a total value of £9,933.84 ($12,503.26). Over the last ninety days, insiders bought 6,222 shares of company stock worth $5,659,584. 0.71% of the stock is owned by corporate insiders.

The Biotech Growth Trust Company Profile

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).